

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

## **1. NAME OF THE MEDICINAL PRODUCT**

BEYONTTRA 356 mg film-coated tablets

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains acoramidis hydrochloride equivalent to 356 mg acoramidis.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Film-coated tablet (tablet).

White, oval film-coated tablets approximately 15 mm × 7.5 mm with the BridgeBio company logo followed by “ACOR” in black ink on one side.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

BEYONTTRA is indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

### **4.2 Posology and method of administration**

Treatment should be initiated by a physician knowledgeable in the management of patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

#### Posology

The recommended dose of acoramidis is 712 mg (two tablets, 356 mg) orally, twice daily, corresponding to a total daily dose of 1 424 mg.

There are no efficacy data in patients with New York Heart Association (NYHA) Class IV (see section 5.1).

#### Missed dose

No double dose should be taken to make up for missed individual doses. Dosing should resume at the next scheduled time.

#### Special populations

##### *Elderly*

No dose adjustment is required in elderly patients (≥ 65 years, see section 5.2).

### *Renal impairment*

Based on low renal clearance of acoramidis, no dose adjustment is required (see section 5.2). Data in patients with severe renal impairment (creatinine clearance < 30 mL/min) are limited (see sections 4.4 and 5.2) and there are no data for patients on dialysis. Hence acoramidis should be used with caution in this population.

### *Hepatic impairment*

Acoramidis has not been studied in patients with hepatic impairment and therefore is not recommended for use in this population (see sections 4.4 and 5.2).

### *Paediatric population*

There is no relevant use of acoramidis in the paediatric population for the indication of “the treatment of wild-type or variant transthyretin amyloidosis with cardiomyopathy”.

### Method of administration

Oral use.

The film-coated tablets should be swallowed whole. BEYONTTRA can be taken with water, with or without food.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

## **4.4 Special warnings and precautions for use**

### Hepatic impairment

Acoramidis has not been studied in patients with hepatic impairment and therefore is not recommended for use in this population (see sections 4.2 and 5.2).

### Renal impairment

Data in patients with severe renal impairment (creatinine clearance < 30 mL/min) are limited (see sections 4.2 and 5.2) and there are no data for patients on dialysis. Hence acoramidis should be used with caution in this population.

### Renal haemodynamic parameters

Patients treated with acoramidis experienced an initial decrease in estimated glomerular filtration rate (eGFR) in the first month of treatment and a corresponding increase in measured serum creatinine (see section 5.1).

This change in eGFR and serum creatinine was non-progressive, reversible in those patients whose treatment was interrupted, and not associated with kidney injury, consistent with a renal haemodynamic effect.

### Information about excipients

#### *Sodium*

This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

## 4.5 Interaction with other medicinal products and other forms of interaction

### Effect of acoramidis on other medicinal products

#### *Transporter systems*

Based on a clinical study in healthy adult volunteers, inhibition of organic anion transporter (OAT)-1 and -3 is not expected to result in clinically relevant drug-drug interactions with OAT-1 and OAT-3 substrates (e.g., non-steroidal anti-inflammatory medicines, bumetanide, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, zidovudine, zalcitabine).

Based on an *in vitro* study, no drug-drug interaction with co-administered breast cancer resistance protein (BCRP) substrates is anticipated at clinically relevant concentrations.

Based on *in vitro* studies, acoramidis is unlikely to cause any clinically relevant uridine 5'-diphospho (UDP)-glucuronosyl transferase-dependent or Cytochrome P450-dependent interactions. However, acoramidis was shown to be an inhibitor of CYP2C8 and CYP2C9 *in vitro*. No *in vivo* study has been performed. Therefore, concomitant CYP2C8 and CYP2C9 substrates with narrow therapeutic index should be used with caution.

### Effect of other medicinal products on acoramidis

#### *Diuretics*

Based on population pharmacokinetic (PK) analysis, concomitant diuretic use in patients does not affect steady-state plasma acoramidis concentrations.

#### *Breast Cancer Resistance Protein inhibitors*

Acoramidis is a substrate for BCRP. Based on an *in vitro* study, a clinically relevant interaction with BCRP inhibitors is not expected.

#### *Gastric acid reducing agents*

No dedicated *in vivo* drug-drug interaction study with gastric acid reducing agents was performed. Thus, the effect of gastric acid reducing agents on the pharmacokinetics of acoramidis is unknown. Despite the marked pH dependent solubility of acoramidis in the physiological pH range, no differences were observed in the systemic exposure to acoramidis or in the pharmacodynamic marker (TTR stabilisation) between patients taking acid reducing agents and patients not taking acid reducing agents, in the phase 3 study.

### Effect on laboratory test

Acoramidis may decrease serum concentrations of free thyroxine without an accompanying change in thyroid stimulating hormone (TSH). No corresponding clinical findings consistent with thyroid dysfunction have been observed.

## 4.6 Fertility, pregnancy, and lactation

### Pregnancy

There are no data on the use of acoramidis in pregnant women.

Studies in animals have shown developmental toxicity at a dose which also caused maternal toxicity (see section 5.3). Acoramidis is not recommended during pregnancy and in women of childbearing potential not using contraception.

## Breast-feeding

It is unknown whether acoramidis or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded (see section 5.3). Acoramidis should not be used during breast-feeding.

## Fertility

No human data on fertility is available. Impairment of fertility has not been observed in non-clinical studies in supratherapeutic exposures.

### **4.7 Effects on ability to drive and use machines**

BEYONTTRA has no or negligible influence on the ability to drive and use machines.

### **4.8 Undesirable effects**

#### Summary of the safety profile

Based on the clinical study, the most frequently reported adverse reactions were diarrhoea (11.6%) and gout (11.2%).

#### Tabulated list of adverse reactions

The safety data reflect exposure of 421 participants with ATTR-CM to acoramidis 712 mg (as two tablets of 356 mg) administered orally twice daily in a pivotal Phase 3 randomised, double-blind, placebo-controlled study of 30 months fixed treatment duration in patients diagnosed with ATTR-CM.

Adverse reactions are listed below by MedDRA System Organ Class (SOC) and frequency categories using the standard convention: Very common ( $\geq 1/10$ ), Common ( $\geq 1/100$  to  $< 1/10$ ), and Uncommon ( $\geq 1/1\ 000$  to  $< 1/100$ ). Adverse reactions listed in the table below are from cumulative clinical data in ATTR-CM participants.

**Table 1: List of adverse reactions**

<b>System Organ Class</b>	<b>Very common</b>
Gastrointestinal disorders	Diarrhoea
Metabolism and nutrition disorders	Gout

#### Description of selected adverse reactions

The majority of events of diarrhoea and gout were non-serious and resolved.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via **the national reporting system** listed in [Appendix V](#).

### **4.9 Overdose**

There is no clinical experience with overdose.

In case of suspected overdose, treatment should be symptomatic and supportive.

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Cardiac therapy, Other cardiac preparations. ATC code: C01EB25.

#### Mechanism of action

Transthyretin amyloid cardiomyopathy is initiated by the dissociation of the transthyretin (TTR) tetramer into its constituent monomers. These misfold and aggregate as oligomeric amyloid precursors that deposit in the heart where they assemble into amyloid fibrils.

Acoramidis is a specific stabiliser of TTR. Acoramidis was designed to mimic the disease protective genetic variant (T119M), through the formation of hydrogen bonds with adjacent serine residues within both thyroxine binding sites of the tetramer. This interaction enhances the stability of the tetramer, inhibiting its dissociation into monomers, thus slowing the amyloidogenic process that results in ATTR-CM.

#### Pharmacodynamic effects

Near-complete transthyretin stabilisation was observed with acoramidis in wild-type and in all amyloidogenic variant genotypes tested, including the most prevalent genotypes V30M (p.V50M), T60A (p.T80A), and V122I (p.V142I). In the ATTRibute-CM study, in patients (wild-type and variant ATTR) treated with acoramidis (712 mg twice daily), near-complete ( $\geq 90\%$ ) TTR stabilisation was observed at the first post-dose initiation assessment (Day 28) and sustained through Month 30. For all post-baseline measurements (from Day 28 through Month 30), the TTR level was higher in the acoramidis group compared with placebo (at Month 30, mean change from baseline 9.1 mg/dL with acoramidis versus 1.3 mg/dL with placebo).

In ATTRibute-CM, the increase in N-terminal prohormone of brain natriuretic peptide (NT-proBNP) at Month 30 favoured acoramidis and was about half the increase seen with placebo. A lower increase in troponin I was also observed with acoramidis versus placebo.

In ATTRibute-CM, the mean serum creatinine (and estimated GFR) at baseline was 110.0  $\mu\text{mol/L}$  (eGFR: 60.9 mL/min/1.73 m<sup>2</sup>) in the acoramidis group and 109.0  $\mu\text{mol/L}$  (eGFR: 61.0 mL/min/1.73 m<sup>2</sup>) in the placebo group. At Day 28, there was a change from baseline in the mean serum creatinine (eGFR) that was greater in the acoramidis group (observed values on Day 28 serum creatinine: 129.3  $\mu\text{mol/L}$ , eGFR: 52.4 mL/min/1.73 m<sup>2</sup>) compared with the placebo group (observed values on Day 28 serum creatinine: 110.6  $\mu\text{mol/L}$ , eGFR: 60.0 mL/min/1.73 m<sup>2</sup>). After Day 28, serum creatinine (eGFR) remained stable in the acoramidis group for the remainder of the study. There was a progressive rise in serum creatinine, and corresponding progressive decrease in eGFR, in the placebo group from baseline through Month 30. At Month 30, serum creatinine was 123.4  $\mu\text{mol/L}$  (eGFR: 55.1 mL/min/1.73 m<sup>2</sup>) and 117.2  $\mu\text{mol/L}$  (eGFR: 57.2 mL/min/1.73 m<sup>2</sup>) for acoramidis and placebo respectively. The observed increase in serum creatinine, and corresponding decrease in eGFR, observed in acoramidis treated patients was reversible in the event of an interruption of therapy.

#### *Cardiac electrophysiology*

The maximum dose of acoramidis, 1 780 mg, studied as a single dose in healthy adult volunteers did not have a clinically relevant effect on cardiac conduction or repolarisation (no concentration-QTc effect was observed). These observations indicate a low risk of pro-arrhythmia.

## Clinical efficacy

ATTRibute-CM was a multicentre, international, randomised, double-blind, placebo-controlled clinical study conducted in 632 participants with wild-type or variant (hereditary or de novo) ATTR-CM and heart failure NYHA Class I-III, with current or prior symptoms of heart failure. Participants were randomised in a 2:1 ratio to receive acoramidis 712 mg (n = 421), or matching placebo (n = 211) twice daily for 30 months. Treatment assignment was stratified by whether participants had variant ATTR-CM (ATTRv-CM) or wild-type ATTR-CM (ATTRwt-CM) and baseline disease severity, i.e., NT-proBNP level and renal function as defined by eGFR. Patients with eGFR < 15 mL/min/1.73 m<sup>2</sup> were excluded from participation in the study.

**Table 2: Demographics and baseline characteristics (mITT population<sup>1</sup>)**

Characteristic	Acoramidis N = 409	Placebo N = 202
Age — years		
Mean (standard deviation)	77.3 (6.5)	77.0 (6.7)
Sex — number (%)		
Male	374 (91.4)	181 (89.6)
Female	35 (8.6)	21 (10.4)
TTR genotype <sup>2</sup> — number (%)		
ATTRv	39 (9.5)	20 (9.9)
ATTRwt	370 (90.5)	182 (90.1)
NYHA class — number (%)		
NYHA class I	51 (12.5)	17 (8.4)
NYHA class II	288 (70.4)	156 (77.2)
NYHA class III	70 (17.1)	29 (14.4)
eGFR <sup>2</sup> (mL/min/1.73 m <sup>2</sup> ) – number (%)		
eGFR ≥ 45	344 (84.1)	173 (85.6)
eGFR < 45	65 (15.9)	29 (14.4)
NT-proBNP <sup>2</sup> (pg/mL) – number (%)		
≤ 3 000	268 (65.5)	133 (65.8)
> 3 000	141 (34.5)	69 (34.2)
ATTR NAC stage <sup>3</sup> — number (%)		
I	241 (58.9)	120 (59.4)
II	130 (31.8)	66 (32.7)
III	38 (9.3)	16 (7.9)
History of permanent pacemaker – number (%)	77 (18.8)	38 (18.8)
History of atrial fibrillation – number (%)	236 (57.7)	117 (57.9)

Abbreviations: ATTRv = variant transthyretin amyloid, ATTRwt = wild-type transthyretin amyloid, NAC = National Amyloidosis Centre (London UK), NYHA = New York Heart Association, eGFR = estimated glomerular filtration rate, NT-proBNP = N-terminal prohormone of brain natriuretic peptide, TTR = transthyretin

<sup>1</sup> mITT = modified intent to treat (baseline eGFR ≥ 30 mL/min/1.73 m<sup>2</sup>).

<sup>2</sup> Stratification factors.

<sup>3</sup> NAC Stage I (NT-proBNP ≤ 3 000 pg/mL and eGFR ≥ 45 mL/min/1.73 m<sup>2</sup>), Stage II (NT-proBNP ≤ 3 000 pg/mL and eGFR < 45 mL/min/1.73 m<sup>2</sup> or NT-proBNP > 3 000 pg/mL and eGFR ≥ 45 mL/min/1.73 m<sup>2</sup>), Stage III (NT-proBNP > 3 000 pg/mL and eGFR < 45 mL/min/1.73 m<sup>2</sup>).

Participants were permitted to initiate open label tafamidis if prescribed as a concomitant medicinal product after 12 months in the study. A total of 107 participants received tafamidis, 61 (14.9%) in the acoramidis arm and 46 (22.8%) in the placebo arm.

The primary objective of the study was to establish superiority of acoramidis versus placebo on a hierarchical endpoint that included all-cause mortality (ACM) and cumulative frequency of cardiovascular-related hospitalisation (CVH). Secondary objectives included assessment of ACM, CVH, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score (a measure of quality of life), serum TTR level and NT-proBNP. The main efficacy analyses were conducted in the 611 participants in the modified intent to treat (mITT) population without any adjustment for the introduction of open label tafamidis.

### *Efficacy analysis*

The efficacy analysis applied the stratified Finkelstein-Schoenfeld (F-S) test hierarchically to ACM and CVH over the 30-month study. The method compared each participant to every other participant within each stratum in a pair-wise manner. In this hierarchical approach, participants in each pair are first compared on ACM, and then on CVH only if the comparison on ACM resulted in a tie. The result of this analysis was statistically significant (Table 3).

All-cause mortality was reported in 19.3% and 25.7% of participants in the acoramidis and placebo groups, respectively. The majority (79%) of deaths were cardiovascular (CV)-related with acoramidis demonstrating a 30% relative risk reduction in CV-related mortality compared with placebo. CV-related mortality was reported in 14.9% and 21.3% of participants in the acoramidis and placebo groups, respectively; hazard ratio: 0.709 (95% CI: 0.476, 1.054,  $p = 0.0889$ , Cox proportional hazards model).

A Cox regression analysis indicated a 35.5% decrease in the risk of the composite of ACM or first CV hospitalisation (hazard ratio: 0.645 [95% CI: 0.500, 0.832;  $p = 0.0008$ ]). Separation in the Kaplan-Meier curves was observed at Month 3 and steadily diverged through Month 30 (Figure 1).

The efficacy results on ACM and CVH demonstrated in the mITT population were also observed in the ITT population (all randomised subjects irrespective of baseline eGFR).

**Table 3: Efficacy results on Finkelstein-Schoenfeld analysis, all-cause mortality and cardiovascular-related hospitalisation at Month 30 in ATTRIBUTE-CM (mITT population)**

<b>Parameter</b>	<b>Acoramidis N = 409</b>	<b>Placebo N = 202</b>
Combination of ACM and cumulative frequency of CVH Win ratio (95% CI) F-S <sup>1</sup> p-value	1.464 (1.067, 2.009) $p = 0.0182$	
Number (%) of participants alive at Month 30 <sup>2</sup>	330 (80.7%)	150 (74.3%)
Number (%) of participants with CVH Number of total CVH events Frequency of CVH per year per participant (mean) <sup>3</sup>	109 (26.7%) 182 0.29	86 (42.6%) 170 0.55
Relative risk ratio <sup>4</sup> p-value	0.496 $p < 0.0001$	

Abbreviations: F-S = Finkelstein-Schoenfeld; ACM = all-cause mortality; CVH = cardiovascular hospitalisation; mITT = modified intent-to-treat; CI = confidence interval


- <sup>1</sup> The F-S method compares every participant pair within each stratum in a hierarchical fashion, starting with ACM. If pairs are tied on ACM, they are then assessed on CVH.
- <sup>2</sup> Heart transplantation and cardiac mechanical assist device implantation are considered indicators of approaching end stage. As such, these events are treated in the analysis as equivalent to death. Therefore, such participants are not included in the count of “Number of participants alive at Month 30” even if such participants are alive based on 30-month vital status follow-up assessment. Vital status at Month 30 was known for all participants.
- <sup>3</sup> CVH per year for each participant is calculated as (participant’s total number of observed CVH) / (duration of follow-up in years) and include events of clinical interest (EOCI). EOICI is defined as medical visits



(e.g., emergency department/ward, urgent care clinic, day clinic) of < 24 hours for intravenous diuretic therapy for management of decompensated heart failure.

4 From negative binomial regression model.

**Figure 1: Time to all-cause mortality or first cardiovascular-related hospitalisation**



Subjects Remaining at Risk (Cumulative Events)

	0	3	6	9	12	15	18	21	24	27	30
BEYONTTRA	409 (0)	389 (20)	370 (39)	355 (54)	337 (72)	319 (90)	308 (101)	298 (111)	284 (125)	270 (139)	0 (147)
Placebo	202 (0)	191 (11)	172 (30)	159 (43)	152 (50)	143 (59)	135 (67)	129 (73)	121 (81)	108 (94)	0 (102)

#### 6-Minute Walk Distance (6MWD) and KCCQ

The treatment effect of acoramidis on functional capacity and health status was assessed by the 6MWD and the KCCQ Overall Summary score (KCCQ-OS); composed of the physical limitation, symptom, social limitation and quality of life domains), respectively (Table 4). A treatment effect favouring acoramidis was first observed for 6MWD and KCCQ-OS at Month 18 and Month 3, respectively, and was sustained through Month 30.

**Table 4: 6MWD and KCCQ-OS scores**

Endpoints*	Baseline Mean (SD)		Change from Baseline to Month 30, LS Mean (SE)		Treatment Difference from Placebo LS Mean (96% CI)	p-value
	Acoramidis N = 409	Placebo N = 202	Acoramidis N = 409	Placebo N = 202		
6MWD (metres)	362.78 (103.50)	351.51 (93.83)	-64.65 (5.51)	-104.29 (7.77)	39.64 (20.18, 59.10)	< 0.0001
KCCQ-OS	71.73 (19.37)	70.48 (20.65)	-11.48 (1.18)	-21.42 (1.65)	9.94 (5.79, 14.10)	< 0.0001


Abbreviations: 6MWD = 6-minute walk distance; CI = confidence interval; KCCQ-OS = Kansas City Cardiomyopathy Questionnaire Overall Summary score, LS = least squares, SD = standard deviation, SE = standard error

\* Higher values indicate better health status.

#### Subgroup analysis

Results from the F-S test applied to ACM and CVH (complemented by the win ratio) consistently favoured acoramidis versus placebo across the stratification parameter (wild type or variant), NYHA class and ATTR National Amyloidosis Centre (NAC) stage subgroups (Figure 2).

**Figure 2: Hierarchical combination of all-cause mortality and CV-related hospitalisation, Finkelstein-Schoenfeld and win ratio results overall and by subgroup (mITT population)<sup>1</sup>**



Abbreviations: ACM = all-cause mortality; ATTRwt-CM = wild-type ATTR-CM; ATTRv-CM = variant ATTR-CM; CVH = cardiovascular-related hospitalisation; F-S = Finkelstein-Schoenfeld; NAC = National Amyloidosis Centre (London, UK); NYHA = New York Heart Association; NAC Stage I (NT-proBNP ≤ 3 000 pg/mL and eGFR ≥ 45 mL/min/1.73 m<sup>2</sup>), Stage II (NT-proBNP ≤ 3 000 pg/mL and eGFR < 45 mL/min/1.73 m<sup>2</sup> or NT-proBNP > 3 000 pg/mL and eGFR ≥ 45 mL/min/1.73 m<sup>2</sup>), Stage III (NT-proBNP > 3 000 pg/mL and eGFR < 45 mL/min/1.73 m<sup>2</sup>)

<sup>1</sup> The win ratio is the number of pairs with acoramidis treated-participant “wins” divided by number of pairs with placebo-treated participant “wins.”

## Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with BEYONTRRA in all subsets of the paediatric population in ATTR-CM (see section 4.2 for information on paediatric use).

## **5.2 Pharmacokinetic properties**

### Absorption

The increase in exposure parameters (area under the concentration-time curve [AUC] and maximum concentration [C<sub>max</sub>]) was less than dose-proportional over single (up to 1 780 mg) or multiple (up to 712 mg) twice daily dosing.

Following oral administration, acoramidis is rapidly absorbed and peak plasma concentration of unchanged acoramidis is usually achieved within 1 hour. Increases in plasma concentration were observed for acoramidis doses from 44.5 mg once daily to 712 mg once daily. Plasma exposures appeared to saturate at acoramidis doses over 712 mg to 1 068 mg. A steady state is achieved by 10 days of dosing with 712 mg twice daily, and repeated dosing results in minor (approximately 1.3- to 1.6-fold) accumulation of acoramidis.

The absolute bioavailability is not known; however at least 75-80% of orally administered single 712 mg dose is absorbed based on a human ADME (absorption, distribution, metabolism, excretion) study.

The overall extent of absorption of acoramidis is not influenced by food intake.

## Distribution

The apparent steady state volume of distribution of 712 mg acoramidis dosed twice daily is 654 litres. *In vitro* binding of acoramidis to human plasma proteins is 96.4%. Acoramidis primarily binds to TTR.

## Biotransformation

The metabolism of acoramidis was characterised following the administration of a single oral dose of [<sup>14</sup>C]-acoramidis to healthy adult volunteers. Acoramidis is metabolised predominantly by glucuronidation, with acoramidis-β-D-glucuronide (acoramidis-AG) being the predominant metabolite (7.6% of total circulating radioactivity). Acoramidis-AG is approximately 3-fold less pharmacologically active than acoramidis, has a low potential for covalent binding, and does not meaningfully contribute to pharmacological activity.

## Elimination and excretion

The terminal half-life of acoramidis is approximately 27 hours after a single dose. At steady state, the apparent oral clearance of acoramidis is 15.6 L/h.

After administration of a single oral dose of [<sup>14</sup>C]-acoramidis to healthy adult volunteers, approximately 34% of dose radioactivity was recovered in faeces (acoramidis being the major component) and approximately 68% was recovered in urine. The percent of unchanged acoramidis in the urine was < 10%.

## Special populations

No clinically significant differences in the pharmacokinetics of acoramidis were observed based on age (18.0-89.3 years), race/ethnicity (including Japanese and non-Japanese), sex, or renal impairment (eGFR 25.4-157 mL/min/1.73 m<sup>2</sup>).

Based on population PK modelling, steady-state acoramidis AUC was 37% higher for healthy subjects than for the patient population. Also, relative to White subjects, steady-state AUC was 23% higher for Black subjects and 38% higher for non-White, non-Black subjects. These effects are within the range of inter-individual variability (CV = 38%). The model also predicted lack of clinically significant differences in the pharmacokinetics of acoramidis due to body weight, within the body weights range of 50.9 to 133 kg.

A dedicated renal-impairment study was not conducted because acoramidis is not substantially eliminated by the renal route. However, despite the main metabolite (acoramidis-AG) having no clinically relevant contribution to pharmacological activity in the studied population, data in patients with severe renal impairment (creatinine clearance < 30 mL/min) are limited and there are no data for patients on dialysis. Clearance of the acoramidis metabolite acoramidis-AG might be affected by severe renal impairment resulting potentially in higher systemic exposure of acoramidis-AG. While this potential increase in acoramidis-AG exposure is not expected to have a clinically meaningful contribution to pharmacologic activity, acoramidis should be used with caution in patients with severe renal impairment.

Acoramidis has not been studied in patients with hepatic impairment.

## **5.3 Preclinical safety data**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, developmental and reproductive toxicology (fertility and embryo-foetal development).

In the rat pre- and postnatal development study with acoramidis, decreased pup survival, reduced pup weights, and learning deficits were observed following maternal dose administration during pregnancy

and lactation with acoramidis at 1 000 mg/kg/day. Severe maternal toxicity including mortalities and weight loss during the period of organogenesis was also observed at this dose. The no-observed-adverse-effect-level (NOAEL) in pre- and postnatal development toxicity study in rats were established at the tested dose of 350 mg/kg/day acoramidis, (AUC values were approximatively 21-fold the human exposure at the clinical dose of acoramidis).

Placental transfer and milk excretion studies in animals were not performed.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

#### Tablet core

Microcrystalline cellulose (E 460)  
Croscarmellose sodium (E 468)  
Colloidal hydrated silica (E 551)  
Magnesium stearate (E 470b)

#### Film-coat

Macrogol poly(vinyl alcohol) grafted copolymer (E 1209)  
Talc (E 553b)  
Titanium dioxide (E 171)  
Glyceryl monocaprylocaprate Type I (E 471)  
Poly(vinyl alcohol) (E 1203)

#### Printing ink

Iron oxide black (E 172)  
Propylene glycol (E 1520)  
Hypromellose 2910 (E 464)

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf life**

30 months

### **6.4 Special precautions for storage**

This medicinal product does not require any special storage conditions.

### **6.5 Nature and contents of container**

Blister packs – Thermoformed dual-cavity blisters of PVC/PCTFE with aluminium foil lidding

Pack sizes: 120 tablets in 6 blister strips, each with 10 cavities (2 tablets per cavity)

### **6.6 Special precautions for disposal**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7.       MARKETING AUTHORISATION HOLDER**

BridgeBio Europe B.V.  
Weerdestein 97  
Amsterdam, 1083 GG  
The Netherlands

**8.       MARKETING AUTHORISATION NUMBER**

EU/1/24/1906/001

**9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation:

**10.     DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency: <https://www.ema.europa.eu>.

## **ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

## **A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer responsible for batch release

Rottendorf Pharma GmbH  
Ostenfelder Strasse 51-61  
Ennigerloh, 59320  
Germany

## **B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## **C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European Medicines Agency web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

## **D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**



## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**OUTER CARTON**

**Blister pack - film-coated tablets**

**1. NAME OF THE MEDICINAL PRODUCT**

BEYONTTRA 356 mg film-coated tablets  
acoramidis

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each film-coated tablet contains acoramidis hydrochloride equivalent to 356 mg acoramidis.

**3. LIST OF EXCIPIENTS**

**4. PHARMACEUTICAL FORM AND CONTENTS**

Film-coated tablet

120 film-coated tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Oral use  
Film-coated tablet must be swallowed whole.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

BridgeBio Europe B.V.  
Weerdestein 97  
Amsterdam, 1083 GG  
The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/24/1906/001

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

BEYONTTRA 356 mg

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS**

**BLISTER FOIL**

**1. NAME OF THE MEDICINAL PRODUCT**

BEYONTTRA 356 mg film-coated tablets  
acoramidis

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

BridgeBio (as logo)

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

**B. PACKAGE LEAFLET**

## Package leaflet: Information for the patient

### BEYONTTRA 356 mg film-coated tablets acoramidis

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### What is in this leaflet

1. What BEYONTTRA is and what it is used for
2. What you need to know before you take BEYONTTRA
3. How to take BEYONTTRA
4. Possible side effects
5. How to store BEYONTTRA
6. Contents of the pack and other information

#### 1. What BEYONTTRA is and what it is used for

BEYONTTRA contains the active substance acoramidis (as hydrochloride).

It is used to treat adults with cardiomyopathy (a disease that affects the heart muscle) resulting from transthyretin amyloidosis (ATTR-CM).

In people with transthyretin amyloidosis, a protein called transthyretin (TTR) does not work properly, causing it to break up and form fibrous clusters called amyloids. When amyloids form in the heart, the heart muscle stiffens, and the heart can no longer work normally. BEYONTTRA stabilises TTR, which can prevent it from breaking up and forming amyloids. This helps people whose heart has been affected by transthyretin amyloidosis cardiomyopathy.

#### 2. What you need to know before you take BEYONTTRA

##### Do not take BEYONTTRA

If you are allergic to acoramidis or any of the other ingredients of this medicine (listed in section 6).

##### Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking BEYONTTRA, especially if you have liver or severe kidney problems.

When starting your treatment you may experience changes in your kidney function blood tests, but these changes should not be harmful to your kidneys.

### **Children and adolescents**

BEYONTTRA is not used in children and adolescents. Its use has not been studied in this population.

### **Other medicines and BEYONTTRA**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

BEYONTTRA may change your thyroid blood tests, but these changes should not be harmful to your thyroid function.

### **Pregnancy, breast-feeding and fertility**

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine as it is not known if BEYONTTRA may harm the unborn baby.

It is not known whether this medicine passes into breast milk. If you are breast-feeding or plan to breast feed, ask your doctor or pharmacist for advice before taking this medicine. There are no data on the use of BEYONTTRA in pregnant women.

### **Driving and using machines**

BEYONTTRA has no or negligible influence on your ability to drive and use machines.

### **Sodium**

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

## **3. How to take BEYONTTRA**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is two film-coated tablets (712 mg) taken by mouth twice a day. The total daily dose is 1 424 mg acoramidis.

BEYONTTRA tablets should be swallowed whole. You can take them with water, with or without food.

### **If you take more BEYONTTRA than you should**

Do not take more tablets than your doctor told you to take. Contact your doctor if think you have taken too much of this medicine.

### **If you forget to take BEYONTTRA**

If you forgot to take your tablets, take them at the next usual time. Do not take a double dose to make up for a forgotten dose.

## **If you stop taking BEYONTTRA**

Do not stop taking BEYONTTRA without first speaking to your doctor. Your disease may progress if you stop taking BEYONTTRA.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

## **4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The possible side effects are:

Very common (may affect more than 1 in 10 people)

- diarrhoea
- painful inflammation in the joints (gout)

## **Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system listed in Appendix V](#). By reporting side effects, you can help provide more information on the safety of this medicine.

## **5. How to store BEYONTTRA**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

## **6. Contents of the pack and other information**

### **What BEYONTTRA contains**

- The active substance is acoramidis (as hydrochloride). Each tablet contains acoramidis hydrochloride equivalent to 356 mg acoramidis.
- The other ingredients are: microcrystalline cellulose (E 460), croscarmellose sodium (E 468), colloidal hydrated silica (E 551), magnesium stearate (E 470b), macrogol poly(vinyl alcohol) grafted copolymer (E 1209), talc (E 553b), titanium dioxide (E 171), glyceryl monocaprylocaprate Type I (E 471), poly(vinyl alcohol) (E 1203), iron oxide black (E 172), propylene glycol (E 1520), hypromellose 2910 (E 464).  
See section 2 for information regarding sodium.



## What BEYONTTRA looks like and contents of the pack

BEYONTTRA 356 mg film-coated tablets (tablets) are white, oval film-coated tablets approximately 15 mm × 7.5 mm with the BridgeBio company logo followed by “ACOR” in black ink printed on one side.

BEYONTTRA is available in dual-cavity blisters of PVC/PCTFE with aluminium foil lidding in a pack containing 120 tablets.

### Marketing Authorisation Holder

BridgeBio Europe B.V.  
Weerdestein 97  
Amsterdam, 1083 GG  
The Netherlands

### Manufacturer

Rottendorf Pharma GmbH  
Ostenfelder Strasse 51-61  
Ennigerloh, 59320  
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

### België/Belgique/Belgien

Bayer SA-NV  
Tél/Tel: +32-(0)2-535 63 11

### Lietuva

UAB Bayer  
Tel. +37 05 23 36 868

### България

Байер България ЕООД  
Тел.: +359 (0)2 4247280

### Luxembourg/Luxemburg

Bayer SA-NV  
Tél/Tel: +32-(0)2-535 63 11

### Česká republika

Bayer s.r.o.  
Tel: +420 266 101 111

### Magyarország

Bayer-Hungária Kft.  
Tel.: +36 1 487 4100

### Danmark

Bayer A/S  
Tlf.: +45 45 23 50 00

### Malta

Alfred Gera and Sons Ltd.  
Tel: +35 621 44 62 05

### Deutschland

Bayer Vital GmbH  
Tel: +49 (0)214-30 513 48

### Nederland

Bayer B.V.  
Tel: +31-23 – 799 1000

### Eesti

Bayer OÜ  
Tel: +372 655 8565

### Norge

Bayer AS  
Tlf: +47 23 13 05 00

### Ελλάδα

Bayer Ελλάς ABEE  
Τηλ: +30-210-61 87 500

### Österreich

Bayer Austria Ges.m.b.H.  
Tel: +43-(0)1-711 46-0

### España

Bayer Hispania S.L.  
Tel: +34-93-495 65 00

### Polska

Bayer Sp. z o.o.  
Tel: +48 22 572 35 00

### France

Bayer HealthCare  
Tél (N° vert): +33-(0)800 87 54 54

### Portugal

Bayer Portugal, Lda.  
Tel: +351 21 416 42 00

**Hrvatska**

Bayer d.o.o.  
Tel: +385-(0)1-6599 900

**Ireland**

Bayer Limited  
Tel: +353 1 216 3300

**Ísland**

Icepharma hf.  
Sími: +354 540 8000

**Italia**

Bayer S.p.A.  
Tel: +39 02 397 8 1

**Κύπρος**

NOVAGEM Limited  
Τηλ: +357 22 48 38 58

**Latvija**

SIA Bayer  
Tel: +371 67 84 55 63

**România**

SC Bayer SRL  
Tel: +40 21 529 59 00

**Slovenija**

Bayer d. o. o.  
Tel: +386 (0)1 58 14 400

**Slovenská republika**

Bayer spol. s r.o.  
Tel. +421 2 59 21 31 11

**Suomi/Finland**

Bayer Oy  
Puh/Tel: +358- 20 785 21

**Sverige**

Bayer AB  
Tel: +46 (0) 8 580 223 00

**This leaflet was last revised in**

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:  
<https://www.ema.europa.eu>